Immuno-oncology
Conference Coverage
Immunotherapies under investigation in newly diagnosed B-ALL
SAN FRANCISCO – Researchers are testing blinatumomab and inotuzumab ozogamicin as first-line treatment in B-cell acute lymphoblastic leukemia.
Conference Coverage
OS benefit with pembrolizumab endures long-term in advanced NSCLC
BARCELONA – First-line pembrolizumab provides a durable long-term OS benefit, compared with that of chemotherapy, in patients with advanced...
Conference Coverage
CT103A elicits responses after prior CAR T-cell relapse
BOSTON – Three of four patients who had failed a prior CAR T-cell therapy achieved a stringent complete response after CT103A.
From the Journals
Cancer patients increasingly being discharged to subacute rehabilitation facilities
Although the intent may be for patients to become well enough to tolerate immunotherapy, about one-third end up receiving additional cancer-...
From the Journals
Prior antibiotic use lowers checkpoint inhibitor response and survival
Patients who take antibiotics in the 30 days prior to starting checkpoint inhibitor therapy for cancer have significantly lower overall survival...
From the Journals
Nivolumab falls short in ccRCC patients with brain metastases
Nivolumab produced an intracranial response rate of 12% in patients with clear cell renal cell carcinoma and previously untreated brain metastases...
From the Journals
Nivolumab yields long-term survival benefit in advanced NSCLC
In a pooled analysis of four studies, the 4-year overall survival with nivolumab was 14%, compared with historical data demonstrating overall...
From the Journals
Pretreatment CT data may help predict immunotherapy benefit in ovarian cancer
Fewer sites of disease and lower intratumor heterogeneity on contrast-enhanced CT may indicate a higher likelihood of durable response to immune...
From the Journals
Immune-related toxicities, hospitalization common with checkpoint inhibitor therapy
The most common immune-related adverse events warranting hospital admission were pneumonitis and colitis.
From the Journals
Real-world data for immunotherapy-treated NSCLC found robust
Endpoints seen among patients treated with PD-1/PD-L1 inhibitors in real-world settings were consistent within data sets and similar to those...
From the Journals
Study outlines survival factors with nivolumab
Absence of bone or liver metastases and excellent baseline performance status are linked to 5-year OS in melanoma, RCC, and NSCLC treated with...